healthcarenewswire

The key reasons behind the advance of the digital health market are the widening applications of mobile health (mHealth), rising adoption of smartphones and tablets, and increasing government support for such solutions. From its value of $73.1 billion in 2017, the market is projected to grow at a 21.1% CAGR during 2018–2023 (forecast period), to reach $223.7 billion in 2023. Digital health refers to the use of mobile devices and information technology to offer various healthcare services.

When segmented by technology, the market categories are telemedicine, healthcare analytics, electronic health record (EHR), and mHealth. Of these, mHealth led the digital health market in 2017, with a 31.5% share, which is predicted to rise to 59.1% in 2023, at a 33.5% CAGR during the forecast period. This would be due to the increasing support of governments across the world for the adoption of this technology and surging awareness of people on the subject.

The increasing adoption of DOA testing at the organizational level, growing number of road accidents and deaths, and rising consumption of illicit drugs are some of the reasons behind the growth of the DOA testing market. In 2016, the market generated a revenue of $4.8 billion, and it is predicted to advance at a CAGR of 9.6% during the forecast period (2017–2023). Drug testing refers to the technical analysis of sweat, blood, saliva, urine, breath, and hair samples to detect the presence of cocaine, cannabis, and alcohol. 

Based on product, the drug of abuse testing market is bifurcated into consumable and equipment. Of these, during the historical period (2013–2016), the consumable bifurcation led the market in terms of revenue, and it is predicted to continue leading it during the forecast period. The reason behind the rapid growth of consumables is that these are handy and available for on-site testing for various types of drugs. Consumables include products such as rapid test kits that are used for the testing of illicit drugs.

The global point-of-care diagnostics market is witnessing growth, due to miniaturization of point-of-care testing devices, technological advancement of point-of-care devices, and healthcare decentralization. Based on product, the glucose monitoring kits segment is the largest contributor to the global point-of-care diagnostics market, due to increasing prevalence of lifestyle associated diseases, such as diabetes; whereas, the cardiac markers and infectious diseases segments are expected to grow at the fastest rate in the coming years.

The massive unexplored point-of-care diagnostics market in the emerging economies is creating ample opportunities for the growth of the global point-of-care diagnostics market, in the coming years. The advanced research and development activities and new product developments by the major players are supporting the demand of point-of-care devices, with better and cost effective point-of-care diagnostics, thus fuelling the growth of the global point-of-care diagnostics market.

The rising concern associated with radiation exposure, increasing awareness and industry initiatives regarding the issue, and surging prevalence of chronic diseases are some of the factors responsible for the growth of the radiation dose management market. In 2016, the market generated a revenue of $129.8 million, and it is expected to attain a size of more than $1700.0 million by 2023, advancing at a CAGR of 46.0% during the forecast period (2017–2023).

RDM refers to a solution that can be integrated with medical systems, such as electronic health record (EHR), picture archiving and communication system (PACS), and radiology information system (RIS), to monitor, archive, and track the radiation exposure and aid in improving patient safety. Based on product, the radiation dose management market is bifurcated into solutions and services. Of these, during the historical period (2013–2016), solutions dominated the market, and these are projected to continue dominating it during the forecast period.

A recent trend observed in the tissue diagnostics industry is increasing usage of immunohistochemistry products as companion diagnostics devices. Increasing prevalence of cancer has fuelled the demand of better diagnostic techniques, which could detect cancer in the earliest stage. According to the WHO, in 2012, there were 14 million new cancer cases and 8.2 million cancer related deaths worldwide.

The global tissue diagnostics market is categorized on the basis of product type, technology, application, and end-user. Based on product type, the tissue diagnostics market can be categorized as instruments and consumables. On the basis of technology, the tissue diagnostics market is categorized as digital pathology and workflow management, in situ hybridization, immunohistochemistry, and special staining. The immunohistochemistry segment leads the global tissue diagnostics market in terms of market size.

The global medical tourism market is growing significantly due to high cost of healthcare expenditure in developed countries. According to Centers for Disease Control and Prevention, approximately 750,000 U.S. people travel out of the country for medical care each year. In addition, rise in aging population, reduced cost of procedure in developing countries, and high standards of medical care at a reasonable price are expected to support the medical tourism market to grow in the coming years. Aging increases the risk of diseases, such as heart disease, gastrointestinal diseases and lifestyle associated diseases. According to the World Health Organization, the population of 60 years and above is expected to rise to 15% in 2050.

Medical tourism refers to travelling to another country for medical treatment. Patients may go for medical care to another country for a range of reason, such as decreased cost, or to receive a procedure or therapy not available in their country. Services ranging from essential treatment to different kind of alternative treatments are provided through medical tourism. Cosmetic surgery, orthopedic surgery, weight loss surgery, heart surgery, oncologic care, reproductive treatment and dental treatment are some of the common procedures that people undergo on medical tourism.

The global biomaterials market is growing at a significant rate, due to increasing healthcare expenditure, growing geriatric population and increasing incidence of cardiovascular diseases. The technological advancement in biomaterials, growing demand of implantable devices, and increasing incidence of hip and knee replacements are also driving the growth of the global biomaterial market. However, factors such as strict regulatory requirements for approval of biomaterials and limitations of biomaterials are inhibiting growth of the market globally.

Geographically, North America dominated the global market of biomaterial in 2015. Asia-Pacific is expected to witness the fastest growth, a CAGR of 18.3% during the forecast period. This is due to increasing geriatric population, increasing healthcare expenditure, increasing research & development, and growing incidence of cardiovascular diseases in the region.

Growing demand for remote patient monitoring, mHealth technologies, and advanced healthcare information system, as well as increasing prevalence of chronic disease and rising government support are driving the market for IoT healthcare. Valued at $56.1 billion in 2017 by P&S Intelligence, the IoT healthcare market is projected to witness a CAGR of 30.2% during the forecast period 2018–2023. The study also estimated its 2023 size to be $267.6 billion.

The molecular cytogenetics market is projected to witness fastest growth in APAC, at CAGR of 11.8%, mainly due to the large population in the region, untapped market and entry of global players in the industry to offer cytogenetic testing. Government initiatives such as mandatory testing, funding and training programs to the researchers are some other factors that are propelling the growth of the market in the region.

Get report sample at@ http://bit.ly/2kS1GfJ